Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03649711 · ClinicalTrials.gov registry record · Phase 3
Chronic Kidney Disease (CKD) Platelet Study
A Phase 3 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT03649711 is a Phase 3 study that has completed, run by University of Arkansas. The registered enrollment target is 76 participants.
The verdict
NCT03649711, a Phase 3 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.
Interventions
- DRUG Aspirin 81 mg
- DRUG Ticagrelor 90mg
- DRUG Clopidogrel 75mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03649711
The ClinicalTrials.gov registry entry for NCT03649711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aspirin 81 mg is the first listed.
NCT03649711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03649711 about?
NCT03649711 is a clinical study titled "Chronic Kidney Disease (CKD) Platelet Study". This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to...
What is the current status of trial NCT03649711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2018-11-01. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT03649711?
The interventions under investigation include: Aspirin 81 mg (DRUG), Ticagrelor 90mg (DRUG), Clopidogrel 75mg (DRUG).
Who is sponsoring clinical trial NCT03649711?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.